[A24-59] Dostarlimab (endometrial cancer) - Addendum to Project A23-143
Last updated 20.06.2024
Project no.:
A24-59
Commission:
Commission awarded on 07.05.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with mismatch repair deficient / microsatellite instability‑high primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy
After addendum now:
- Patients with primary FIGO stage III: added benefit not proven
- Patients with primary FIGO stage IV: hint of minor added benefit
- Patients with recurrent disease: indication of major added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A24-59_en
| Project no. | Title | Status |
|---|---|---|
| A23-143 | Dostarlimab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-06-20 A G-BA decision was published.